Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros













Base de datos
Intervalo de año de publicación
1.
Mol Biol Rep ; 51(1): 349, 2024 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-38401023

RESUMEN

BACKGROUND: Alzheimer's disease (AD) is a neurological condition that may lead to dementia as well as a slow and steady decline in cognitive ability. Finding early signs that may be used in the diagnosis of AD is still a difficult aim to achieve in the field of medical practice. METHODS AND RESULTS: The purpose of this research was to investigate to determine any differences in the gene expression patterns of crystallin mu (CRYM) and sialic acid-binding immunoglobulin-like lectin 10 (SIGLEC10) in whole blood samples obtained from fifty individuals who were diagnosed with AD and fifty individuals as a control group. When compared with controls, it was discovered that the expression of the CRYM gene was substantially decreased in AD patients, but the expression of the SIGLEC10 gene was significantly higher. A positive correlation between CRYM and SIGLEC10 was noticed solely in patients with AD. Furthermore, assessing the diagnostic value of these genes, CRYM and SIGLEC10 transcript levels displayed an area under the curve (AUC) of 0.74 and 0.81, respectively. CONCLUSIONS: These results suggest that alterations in CRYM and SIGLEC10 expression may be implicated in AD pathology and that these genes expression levels can potentially serve as biomarkers for early detection and diagnosis of AD. Nevertheless, further validation of these findings requires the inclusion of more extensive and heterogeneous cohorts. The findings derived from this study possess the capability to offer a significant contribution towards the progression of innovative diagnostic and therapeutic strategies for AD.


Asunto(s)
Enfermedad de Alzheimer , Cristalinas mu , Humanos , Enfermedad de Alzheimer/diagnóstico , Enfermedad de Alzheimer/genética , Biomarcadores , Expresión Génica , Lectinas/genética , Receptores de Superficie Celular
2.
BMC Res Notes ; 14(1): 216, 2021 May 31.
Artículo en Inglés | MEDLINE | ID: mdl-34059110

RESUMEN

OBJECTIVE: Helicobacter pylori is one of the most common causes of gastric infections in humans. It is estimated that approximately 50% of people around the world are infected with this bacterium. This study aimed to determine the antibiotic resistance pattern, as well as the frequency of cagA and vacA genes in H. pylori isolates obtained from patients in the clinical centers in Tabriz city, Iran. RESULTS: The culture method detected 100 (45.25%) H. pylori isolates from 221 biopsy samples during 3 years. The results showed that 63% and 81% of the isolates were positive for cagA and vacA genes, respectively. The highest resistance of isolates was seen against metronidazole (79%) and amoxicillin (36%), respectively. Also, the isolates showed the least resistance to tetracycline (8%).


Asunto(s)
Helicobacter pylori , Antígenos Bacterianos/genética , Proteínas Bacterianas/genética , Farmacorresistencia Microbiana , Genotipo , Helicobacter pylori/genética , Humanos , Irán/epidemiología
3.
Mol Biol Rep ; 48(1): 951-960, 2021 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-33389533

RESUMEN

Today, the increasing rate of cancer-related mortality, has rendered cancer a major global challenge, and the second leading cause of death worldwide. Conventional approaches in the treatment of cancer mainly include chemotherapy, surgery, immunotherapy, and radiotherapy. However, these approaches still come with certain disadvantages, including drug resistance, and different side effects such as gastrointestinal (GI) irritation (e.g., diarrhea, mucositis). This has encouraged scientists to look for alternative therapeutic methods and adjuvant therapies for a more proper treatment of malignancies. Application of probiotics as an adjuvant therapy in the clinical management of cancer appears to be a promising strategy, with several notable advantages, e.g., increased safety, higher tolerance, and negligible GI side effects. Both in vivo and in vitro analyses have indicated the active role of yeast probiotics in mitigating the rate of cancer cell proliferation, and the induction of apoptosis through regulating the expression of cancer-related genes and cellular pathways. Strain-specific anti-cancer activities of yeast probiotics strongly suggest that their administration along with the current cancer therapies may be an efficient method to reduce the side effects of these approaches. The main purpose of this article is to evaluate the efficacy of yeast probiotics in alleviating the adverse effects associated with cancer therapies.


Asunto(s)
Neoplasias Colorrectales/terapia , Terapia Combinada/métodos , Diarrea/terapia , Probióticos/uso terapéutico , Saccharomyces/fisiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Bifidobacterium/fisiología , Quimioradioterapia Adyuvante/métodos , Neoplasias Colorrectales/inmunología , Neoplasias Colorrectales/microbiología , Neoplasias Colorrectales/patología , Diarrea/inmunología , Diarrea/microbiología , Diarrea/patología , Manejo de la Enfermedad , Humanos , Inmunoterapia/métodos , Lactobacillaceae/fisiología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA